Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.78 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9137849 | 0.91 | SRD5A2 (0.75) | TDP1SRD5A2MEN1KMT2APLA2G4B | |
| 4-Nitrobenzoic Acid SCHEMBL43476 | 0.88 | TDP1 (1.00) | TDP1SRD5A2MEN1KMT2APOLB | |
| Terephthalic Acid SCHEMBL28023943 | 0.88 | TDP1 (1.00) | TDP1SRD5A2MEN1KMT2APOLB | |
| SCHEMBL8094425 | 0.87 | SRD5A2 (0.67) | TDP1SRD5A2POLBCES1CA1 | |
| SCHEMBL8094198 | 0.87 | SRD5A2 (0.67) | TDP1SRD5A2POLBCES1CA1 | |
| SCHEMBL9018930 | 0.87 | SRD5A2 (0.67) | TDP1SRD5A2POLBCES1CA1 | |
| SCHEMBL8095914 | 0.87 | SRD5A2 (0.67) | TDP1SRD5A2POLBCES1CA1 | |
| 4-Nitrobenzoic Acid SCHEMBL17332065 | 0.86 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2APOLB | |
| 4-Nitrobenzoic Acid SCHEMBL11331124 | 0.86 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2APOLB | |
| 4-Nitrobenzoic Acid SCHEMBL1566327 | 0.86 | TDP1 (0.95) | TDP1SRD5A2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0902018-B1 | 2-(Arylphenyl)amino-imidazoline derivatives | HOFFMANN LA ROCHE (CH) | 2008-07-23 | — | — | EP | disclosed |
| US-7141584-B2 | guanidine derivatives containing phenyl and imidazole rings; useful for treating pain conditions from a wide variety of causes such as cancer, trauma, surgery, inflammation etc. | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2004-06-24 | — | — | US | disclosed |
| US-6693200-B2 | IP RECEPTOR ANTAGONISTS; ANTIINFLAMMATORIES AND ANALGESICS | SYNTEX (U.S.A.) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | BLEY KEITH ROGER (US) | 2003-12-11 | — | — | US | disclosed |
| US-6596876-B2 | Prostaglandin I2 inhibitors | SYNTEX (U.S.A.) LLC | 2003-07-22 | — | — | US | disclosed |
| CN-1110484-C | 2-(arylphenyl) amino-imidazoline derivatives | HOFMMANN LA ROCHE AG F (CH) | 2003-06-04 | — | — | CN | disclosed |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | BLEY KEITH ROGER (US) | 2003-02-20 | — | — | US | disclosed |
| US-6472536-B1 | SUCH AS 2-(4-(4-CYCLOPENTYLOXYBENZYL)PHENYL)AMINO-IMIDAZOLINE; ANTINOCICEPTIVE AGENTS; IP RECEPTOR ANTAGONISTS; TREATING INFLAMMATORY PAIN | SYNTEX (U.S.A.) LLC | 2002-10-29 | — | — | US | disclosed |
| US-6184242-B1 | 2-(substituted-phenyl)amino-imidazoline derivatives | SYNTEX USA (LLC) | 2001-02-06 | — | — | US | disclosed |
| CN-1216762-A | 2-(arylphenyl) amino-imidazoline derivatives | HOFMMANN LA ROCHE AG F (CH) | 1999-05-19 | — | — | CN | disclosed |
| EP-0902018-A2 | 2-(Arylphenyl)amino-imidazoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-03-17 | — | — | EP | disclosed |
| US-5464912-A | Adduct with rodlike mesogenic moiety, adduct made by reacting polyepoxide with nitro/so/ compound having epoxy-reactive hydrogen; conversion of hydroxyl product to ether, ester, halide, urethane, ketone, alkane; reducing nitro/so/ to amine | THE DOW CHEMICAL COMPANY (US) | 1995-11-07 | — | — | US | disclosed |
| US-5344898-A | Curable composition with stilbene groups and molecular orientation | THE DOW CHEMICAL COMPANY (US) | 1994-09-06 | — | — | US | disclosed |
| US-5298575-A | Consists of at least one compound having more than one vicinal epoxide group and at least one amine terminated adduct containing one or more mesogenic moities | THE DOW CHEMICAL COMPANY (US) | 1994-03-29 | — | — | US | disclosed |
| US-4171976-A | Homopolymerization inhibition of photographic hardeners | EASTMAN KODAK COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229123-A1 | Antiinflammatory agents; antiallergens; lipoxygenase or phospholipase inhibitors | LTB4R2, LTB4R, ALOX5 | TDP1 2963/4885SRD5A2 638/4885MEN1 4692/4885 |
| US-20040122053-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, GRK2, TBXA2R | TDP1 3471/4885SRD5A2 1101/4885MEN1 1657/4885 |
| US-20030036655-A1 | 2-(substituted-phenyl)amino-imidazoline derivatives | GIPR, TBXA2R, GRK2 | TDP1 3302/4885SRD5A2 861/4885MEN1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.